Original Article

Risk stratification of PD-L1 expression in non-small cell lung cancer: a predictive model for prognosis

Longfei Jia, Yi Yang, Xinye Xia, Feixuan Luo, Yujie Wang, Yinghan Jin, Henglun Liang, Liangyong He, Guojie Lu, Yuanzhou Wu, Hui Li, Qunqing Chen, Dan Mu, Yingwei Zhang, Kaican Cai, Yang Wang

Abstract

Immune checkpoint inhibitors (ICIs) have become the standard of care for non-small cell lung cancer (NSCLC) patients with programmed cell death ligand-1 (PD-L1) expression ≥1%. However, not all patients benefit equally from this treatment. This study develops a predictive model for risk stratification in NSCLC patients, integrating clinical, radiological, genomic, and PD-L1 expression data to enhance immunotherapy outcomes.

Article Options

Download Citation

Share